ARCHIVES

Phase II Imbruvica Trial Shows 47% of MCL Patients Alive at 27-Month Median Follow-up

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

New Source of Research Funds? As Clinton Derails Tobacco Deal, Prospects May Brighten for Tougher Measures In ‘98

September 19, 1997

NCI Names Brawly Director of Office of Special Populations

June 21, 1996

Cooperative Group Chairmen, OPRR Seek Agreement On Assurances

January 6, 1984

Congress Urges CMS To Soften Proposal For Coverage Of ESAs in Oncology.

July 20, 2007

ACS President & COO Resigns Unexpectedly; Was Seen as Contender for CEO Position

December 19, 2014

Obey Insists NCI Pressured IARC Into Softening Report On Benzene Risk

August 20, 1982